Prolotherapy is not a hoax, but it’s not a proven cure-all either. It sits in a gray zone: a treatment with a plausible biological mechanism and some positive clinical evidence for specific conditions, but not enough consistent proof to earn endorsement from major medical organizations. Medicare does not cover it, and the American College of Rheumatology actively recommends against it for knee osteoarthritis. Yet some well-designed trials show real benefits for certain injuries, particularly tendon problems like tennis elbow.
The honest answer is more nuanced than “it works” or “it’s fake.” Here’s what the evidence actually shows.
What Prolotherapy Does in the Body
The most common form of prolotherapy involves injecting a concentrated sugar solution (usually dextrose) into damaged tendons, ligaments, or joints. The high concentration of sugar creates osmotic stress at the injection site, essentially dehydrating cells in the immediate area. This triggers a controlled inflammatory response, drawing in immune cells that release growth factors. Over the following weeks, fibroblasts (the cells responsible for building connective tissue) ramp up production of type I and type III collagen. New blood vessels also form in the area, restoring blood flow to tissue that may have been poorly supplied.
The final phase involves the body reorganizing and realigning those new collagen fibers, which theoretically strengthens the repaired tissue. This entire process mirrors how the body naturally heals an acute injury. The idea behind prolotherapy is that chronic injuries sometimes stall in the healing process, and a controlled irritation can restart it.
This mechanism is biologically plausible, and lab studies have confirmed that dextrose does stimulate fibroblast activity and collagen production. The real question is whether this translates to meaningful pain relief and functional improvement in actual patients.
Where the Evidence Is Strongest
The best clinical support for prolotherapy comes from tendon injuries. A meta-analysis of prolotherapy for lateral epicondylitis (tennis elbow) found that dextrose injections reduced pain intensity more than active control treatments at 12 weeks, with improvements in arm and hand function that met the threshold for clinical relevance. The functional gains were particularly consistent across studies, with low variability between trials.
For knee osteoarthritis, results are more mixed but still interesting. In randomized controlled trials comparing dextrose prolotherapy to saline injections, patients receiving prolotherapy showed an average improvement of 25.2 points on a standard knee pain and function scale at six months, compared to 9.5 points in the saline group. That’s a meaningful gap, though it’s worth noting that the saline group also improved, which complicates interpretation (saline injections into joints can themselves have therapeutic effects).
Where It Falls Short
For rotator cuff tendinopathy, prolotherapy doesn’t appear to work better than control treatments. A systematic review of eight studies involving 431 participants found no significant differences in pain scores or overall shoulder function between prolotherapy and control groups. The only measurable benefit was a modest improvement in shoulder abduction (the ability to raise your arm out to the side), gaining about 7 extra degrees of motion. That’s statistically significant but not clinically dramatic.
The broader problem plaguing prolotherapy research is inconsistency. Studies vary widely in the concentration of dextrose used, the number of injections given, the specific injection sites, and what they compare prolotherapy against. Some trials compare it to saline (which may itself be therapeutic when injected into a joint), while others compare it to exercise therapy or corticosteroid injections. This makes it difficult to draw firm conclusions across the full body of research.
Why Major Medical Bodies Remain Skeptical
The American College of Rheumatology’s most recent guidelines (2019) recommend against prolotherapy for knee osteoarthritis, citing a limited number of trials and significant variability in study methods. Medicare has maintained a non-coverage policy since 1999, stating that the medical effectiveness of prolotherapy “has not been verified by scientifically controlled studies.” Most private insurers follow Medicare’s lead. If you pursue prolotherapy, expect to pay out of pocket, typically for a series of 3 to 6 sessions spaced 4 to 6 weeks apart.
This lack of institutional support doesn’t necessarily mean the treatment is worthless. It means the evidence hasn’t crossed the threshold that guideline committees require before issuing a positive recommendation. For context, many widely used treatments in orthopedics (platelet-rich plasma, certain types of knee surgery) have faced similar evidence gaps.
Safety Concerns Are Real but Uncommon
Prolotherapy is generally low-risk, but it’s not risk-free. A practitioner survey documented 472 adverse events, the vast majority (80%) related to needle placement rather than the injected solution itself. The most common complications were spinal headaches (164 cases) and pneumothorax, or a collapsed lung (123 cases), both occurring with spinal injections. Nerve damage was reported 54 times, with 5 cases resulting in permanent injury. Nine cases involved more serious spinal complications including meningitis or cord injury.
These numbers come without a clear denominator (we don’t know how many total injections were performed), so calculating a precise complication rate is difficult. But the pattern is clear: injections around the spine carry the highest risk, while peripheral joint and tendon injections appear substantially safer. The skill and training of the practitioner matters enormously.
What This Means for You
Prolotherapy occupies a space between unproven and established. Calling it a hoax overstates the case. There is a real biological mechanism, and for specific conditions like tennis elbow, the clinical evidence is genuinely encouraging. But calling it a reliable treatment also overstates the case. For shoulder problems, the data is underwhelming, and for knee arthritis, the evidence is promising but not yet strong enough to convince guideline panels.
People who benefit most from prolotherapy tend to have chronic tendon or ligament injuries that haven’t responded to physical therapy, in locations where the injection risk is low. If you’re considering it, the practical reality is 3 to 6 sessions over several months, paid out of pocket, with results that may take weeks to emerge since the treatment works by stimulating a gradual healing process rather than providing immediate relief.